India, Sept. 15 -- Arrowhead Pharmaceuticals, Inc. (ARWR) is down 8.93 percent, losing $7.20 to $73.47 on Tuesday. The move comes after the company announced interim topline data from a Phase 1/2a trial of ARO-DIMER-PA, its first investigational RNAi therapeutic dimer designed to simultaneously silence the PCSK9 and APOC3 genes for potential treatment of atherosclerotic cardiovascular disease associated with mixed hyperlipidemia.
Arrowhead Pharmaceuticals is currently trading at $73.47, down from the previous close of $80.67 after opening at $82.82 on Nasdaq. The stock has traded between $72.89 and $83.55 during the session, with trading volume at 1.58 million shares versus average volume of 2.05 million.
googletag.cmd.push(function() { g...